☆ 4.5 Article

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR +, HER2-metastatic breast cancer patients in Japan

BREAST CANCER (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Subsequent-abemaciclib Treatment After Disease Progression on Palbociclib in Patients With ER-positive HER2-negative Metastatic Breast Cancer

Hirohito Seki et al.

Summary: This study investigated the efficacy of continuing cyclin-dependent kinase (CDK) 4 and 6 inhibitors in patients with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) after disease progression on prior-palbociclib. The results showed that the best overall response to prior-palbociclib was the only independent predictive factor for progression-free survival (PFS) in patients receiving subsequent-abemaciclib after disease progression on prior-palbociclib.

ANTICANCER RESEARCH (2022)

Add to Collection

Article Oncology

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer

Masato Takahashi et al.

Summary: In the Japanese subpopulation, abemaciclib plus NSAI was shown to be an effective initial treatment for ABC, with a manageable safety profile, consistent with findings in the overall population.

BREAST CANCER (2022)

Add to Collection

Article Oncology

Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels

Norikazu Masuda et al.

Summary: The purpose of this study was to examine the safety of abemaciclib in Japanese patients with advanced breast cancer. The analysis of data from two phase 3 studies showed that abemaciclib-treated Japanese patients had a higher incidence of diarrhea, neutropenia, and liver function abnormalities compared to the overall safety population. However, these adverse events were manageable with appropriate interventions.

CANCER MANAGEMENT AND RESEARCH (2022)

Add to Collection

Article Oncology

Evaluation of potential complication of interstitial lung disease with abemaciclib and palbociclib treatments

Hideki Nawa et al.

Summary: This study evaluated the clinical incidence of interstitial lung disease caused by abemaciclib and palbociclib, two CDK4/6 inhibitors, and found that both drugs are associated with a potential complication of interstitial lung disease regardless of age. Signals of adverse events were detected in both the JADER and FAERS databases.

CANCER REPORTS (2022)

Add to Collection

Article Oncology

Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report

Akimitsu Maeda et al.

Summary: The CKD4/6 inhibitor abemaciclib is associated with adverse events such as hematological toxicity and increased serum creatinine levels. While abemaciclib concentrations are linked to neutropenia and thrombocytopenia, increased serum creatinine levels may not be a reliable predictor of abemaciclib pharmacokinetics and hematological toxicity.

INVESTIGATIONAL NEW DRUGS (2021)

Add to Collection

Article Oncology

Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan

Yucherng Chen et al.

Summary: This study evaluated patients treated with abemaciclib and diagnosed with ILD in Japan, identifying potential risk factors and highlighting the importance for healthcare providers to consider the benefit-risk profile, inform patients of risks, and regularly monitor treated patients to ensure early detection and treatment of ILD.

BREAST CANCER (2021)

Add to Collection

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

Add to Collection

Article Medicine, General & Internal

Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR+, HER2-metastatic breast cancer

Gebra Cuyun Carter et al.

Summary: This retrospective observational study described the baseline characteristics, real-world treatment patterns, and outcomes of patients with metastatic breast cancer treated with abemaciclib in the United States. The study found that patients benefited from abemaciclib treatment in the real world, similar to results seen in clinical trials. More research is needed to further investigate outcomes associated with abemaciclib treatment.

CURRENT MEDICAL RESEARCH AND OPINION (2021)

Add to Collection

Article Oncology

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy

Kenichi Inoue et al.

Summary: In the Japanese subpopulation analysis of the MONARCH 2 study, abemaciclib plus fulvestrant demonstrated significantly prolonged progression-free survival, higher objective response rate, and good safety profile in treating advanced breast cancer patients. Results were consistent with those of the overall population.

BREAST CANCER (2021)

Add to Collection

Article Oncology

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial

George W. Sledge et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Oncology

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition

Tatsunori Shimoi et al.

BREAST CANCER (2020)

Add to Collection

Article Public, Environmental & Occupational Health

Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study

Emily Heer et al.

Lancet Global Health (2020)

Add to Collection

Article Oncology

The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer

Ru Wang et al.

BMC CANCER (2019)

Add to Collection

Article Oncology

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Stephen Johnston et al.

NPJ BREAST CANCER (2019)

Add to Collection

Article Medicine, General & Internal

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

P. Schmid et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Oncology

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

Matthew P. Goetz et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

Add to Collection

Article Oncology

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Raquel Torres-Guzman et al.

ONCOTARGET (2017)

Add to Collection

Article Oncology

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer

Maura N. Dickler et al.

CLINICAL CANCER RESEARCH (2017)

Add to Collection

Article Oncology

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors

Amita Patnaik et al.

CANCER DISCOVERY (2016)

Add to Collection

Article Oncology

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert et al.

INVESTIGATIONAL NEW DRUGS (2014)

Add to Collection

Editorial Material Health Care Sciences & Services

Newly marketed medications present unique challenges for nonrandomized comparative effectiveness analyses

Jeremy A. Rassen et al.

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2012)

Add to Collection

Article Pharmacology & Pharmacy

Assessing the Comparative Effectiveness of Newly Marketed Medications: Methodological Challenges and Implications for Drug Development

S. Schneeweiss et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)

Add to Collection

Article Oncology

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

M. Elizabeth H. Hammond et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

Add to Collection

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.